Merck Serono and Fast Forward, LLC Announce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis |
18.03.2009
| von Merck Serono SA
18.03.2009, Geneva, Switzerland. Merck Serono, a division of Merck KGaA, Darmstadt Germany, and Fast Forward, LLC, a wholly-owned subsidiary of the American National Multiple Sclerosis Society, today announced a collaborative partnership to evaluate and fund promising multiple sclerosis (MS) research projects. Proposals will be jointly developed by Merck Serono and Fast Forward. Merck KGaA will provide up to $19 million in funding. The funds will support early stage clinical development projects with biotech companies or projects with individual researchers or academic institutions.
It is with great excitement that our organization supports this initiative with Fast Forward, which will explore new avenues to advance new MS treatments with the potential to transform people’s lives,” said Fereydoun Firouz, President and CEO of EMD Serono Inc. in the USA.
--- ENDE Pressemitteilung Merck Serono and Fast Forward, LLC Announce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis ---
Über Merck Serono SA:
In achieving our goals we maximise the return on investment of our shareholders. Our overall aim is to develop innovative products to address unmet medical needs and improve the quality of life of our patients.
Weitere Informationen und Links:
Newsletter abonnieren
Auf diesem Link abonnieren Sie unseren Newsletter und sind stets aktuell informiert.
Eigene News publizieren
Haben Sie eine aktuelle Firmeninformation oder ein Angebot, dass Sie hier publizieren möchten?
Auf diesem Link erfassen Sie die entsprechenden Informationen.